Dorothy I. Shulman

Pediatric Endocrinology

13101 Bruce B Downs Blvd
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: April 29, 2026

Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.

Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.

Journal: Diabetes technology & therapeutics

Published: August 18, 2025

Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.

Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: October 02, 2023

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.

Journal: Diabetes technology & therapeutics

Published: May 30, 2023

Subcutaneous Infusion of rhPTH1-34 During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1.

Subcutaneous Infusion of rhPTH1-34 During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1.

Journal: Journal of the Endocrine Society

Published: December 29, 2021

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: October 25, 2021

Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.

Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.

Journal: Pediatric diabetes

Published: July 11, 2021

Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.

Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.

Journal: European journal of endocrinology

Published: June 25, 2020

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: December 27, 2018

In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.

In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: October 10, 2018

A novel mutation in GLUD1 causing hyperinsulinism-hyperammonemia in a patient with high density of homozygosity on microarray: a case report.

A novel mutation in GLUD1 causing hyperinsulinism-hyperammonemia in a patient with high density of homozygosity on microarray: a case report.

Journal: Journal of medical case reports

Published: April 18, 2015

Poor head growth as a presenting sign of a cortisol-secreting adrenal adenoma in a 2-year-old boy.

Poor head growth as a presenting sign of a cortisol-secreting adrenal adenoma in a 2-year-old boy.

Journal: The Journal of pediatrics

Published: August 01, 2014

Showing 1-12 of 21

Last Updated: 09/26/2026